Methylene blue (MB), a phenothiazine derivative, is currently under clinical trials for Alzheimer's disease (ad) due to its potential to inhibit tau aggregation, a key pathological process in ad. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.